What is the evidence base for Melanotan II?

Melanotan II's evidence base sits at mechanistic + off-label. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The protocol / scheduling / cycling interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

How long until I see results from Melanotan II?

Acute effects from Melanotan II appear within hours of dosing for receptor-level changes. scheduling and cycle endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What is the standard dosing protocol for Melanotan II?

Conventional Melanotan II dosing is 0.25-0.5 mg daily during loading, then 1-2x weekly via subq/intranasal. For scheduling and cycle use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What does Melanotan II stack well with?

For protocol / scheduling / cycling protocols, Melanotan II pairs with compounds on complementary pathways: BPC-157, TB-500, Ipamorelin. These pairings are selected because they engage independent receptor systems from Melanotan II's primary mechanism (Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5)), producing additive or synergistic effects rather than receptor competition.

What are the safety considerations for Melanotan II?

Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history. For scheduling and cycle use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Melanotan II's ~30 min pharmacokinetic profile and subq/intranasal administration route influence the side-effect profile in predictable ways.

What route should I use for Melanotan II?

Melanotan II is delivered by subq/intranasal. The intranasal route is preferred for compounds targeting the central nervous system because it bypasses the BBB via the olfactory pathway. The choice depends on target system and convenience.

Home/ Compounds/ Melanotan II

Melanotan II

Protocol

Protocol design for Melanotan II starts with pharmacokinetics and ends with calendar planning. The compound's ~30 min half-life via subq/intranasal administration places it in the multi-daily-dosing bucket; cycle length is 8-12 weeks with a 4-week off-period; stack integration follows route compatibility and receptor non-overlap principles.

Protocol / Scheduling / Cycling Applications

Multi-Peptide TimingWeekly TimingLoading PhaseTravel ConsiderationsProtocol Calendar

Key Takeaways

Scheduling lens: Melanotan II's ~30 min half-life via subq/intranasal places it in the multi-daily-dosing bucket.
Mechanism: Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5).
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Protocol calendar planning for Melanotan II is shaped by mechanism, pharmacokinetics, and operational reality. Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation. The subsections below work through the daily timing patterns, the 8-12 week cycle structure with calibrated off-period, the stack scheduling principles, and the travel-and-disruption playbook.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Melanotan II protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Melanotan II schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Daily and weekly timing

Melanotan II with a ~30 min half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either Daily during loading, then 1-2x weekly, with consistency mattering more than the absolute clock time of any single dose.

Cycle length and off-cycle planning

Standard Melanotan II cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Protocol / Scheduling / Cycling Applications

Tapered Cycles

For tapered cycles scheduling, Melanotan II is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Off-Time

Schedule design for Melanotan II in off-time starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Multi-Peptide Timing

The most-asked scheduling question for Melanotan II in multi-peptide timing is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Periodised Cycles

For periodised cycles scheduling, Melanotan II is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	0.25-0.5 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.25-0.5 mg	4–6 weeks initial cycle
Protocol focus	SubQ	0.25-0.5 mg	Daily during loading, then 1-2x weekly
Maintenance phase	SubQ	1.25-0.5 mg	Ongoing with periodic pauses

Dose timing for Melanotan II is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Melanotan II stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

Melanotan II + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Melanotan II's mechanism in protocol / scheduling / cycling protocols.
Melanotan II + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Melanotan II's mechanism in protocol / scheduling / cycling protocols.
Melanotan II + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Melanotan II's mechanism in protocol / scheduling / cycling protocols.
Melanotan II + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Melanotan II's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Mechanistic + off-label

Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history.

Lens-specific safety considerations for protocol / scheduling / cycling use of Melanotan II: Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Melanotan analogues and melanocortin receptor pharmacology

PMID 1429592

Melanotan II vs Related Peptides

Compound	Profile	Onset	Best For
Melanotan II	Cyclic α-MSH analogue	~30 min	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Daily timing for Melanotan II?

Pragmatic timing depends on pharmacokinetics: multi-daily dosing for short half-life. Consistent timing matters more than the absolute clock time of any single dose.

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

Can I shift my schedule with travel?

Up to ±8 hours of timing shift has no clinical effect for most peptide schedules. Time-zone changes longer than 8 hours warrant a minor schedule adjustment over 1–2 days to re-anchor the cycle. Cold-chain requirements during travel are the more important operational concern.

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

Is Melanotan II safe during pregnancy or breastfeeding?

Melanotan II, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What is the regulatory status of Melanotan II?

Melanotan II regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level mechanistic + off-label. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For scheduling and cycle use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Clinical Protocol

Start a Melanotan II Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified Melanotan II and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 1024 Da
Sequence length: 7 aa
Half-life: ~30 min
WADA: Not on prohibited list
FDA: Unapproved
Research: Mechanistic + off-label

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan II unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for Melanotan II

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised